Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$14,456 Mln
Revenue (TTM)
$3,357 Mln
Net Profit (TTM)
$972 Mln
ROE
0.1 %
ROCE
4.8 %
P/E Ratio
41.5
P/B Ratio
2.6
Industry P/E
64.27
EV/EBITDA
15
Div. Yield
0.2 %
Debt to Equity
0.5
Book Value
$--
EPS
$--
Face value
--
Shares outstanding
125,441,000
CFO
$5,023.60 Mln
EBITDA
$7,211.63 Mln
Net Profit
$3,630.91 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
PerkinElmer (PKI)
| -16.1 | 1.2 | -4.6 | -14.8 | 6.6 | 8.5 | 13.5 |
|
BSE Sensex*
| 4.5 | 4.1 | 7.7 | 10.5 | 15.7 | 22.1 | 11.5 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2022
|
2021
|
2020
|
2019
|
2018
|
2017
|
2016
|
|---|---|---|---|---|---|---|---|
|
PerkinElmer (PKI)
| -30.3 | 40.4 | 48.2 | 24.0 | 7.8 | 40.8 | -2.1 |
|
S&P Small-Cap 600
| -17.4 | 25.3 | 9.6 | 20.9 | -9.7 | 11.7 | 24.7 |
|
BSE Sensex
| 4.4 | 22.0 | 15.8 | 14.4 | 5.9 | 27.9 | 1.9 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
PerkinElmer (PKI)
|
117.7 | 14,455.8 | 3,357.5 | 396.9 | 16.3 | 5.4 | 41.5 | 2.6 |
| 13.4 | 9,138.0 | 6,685.2 | 715.6 | 16.4 | 12.3 | 12.9 | 1.5 | |
| 250.1 | 7,142.2 | 2,541.1 | -2,228.1 | -106.3 | -31.5 | -- | 1.0 | |
| 248.7 | 6,694.7 | 2,541.1 | -2,228.1 | -106.3 | -31.5 | -- | 1.0 | |
| 61.1 | 8,292.0 | 2,510.8 | 185.6 | 8.8 | 4.5 | 45.7 | 2.0 | |
| 71.8 | 8,769.9 | 12,669.0 | 407.0 | 5.4 | 11.8 | 22.4 | 2.6 | |
| 155.1 | 8,437.6 | 1,973.6 | -494.5 | -11.4 | -41 | -- | 8.8 | |
| 98.1 | 5,840.8 | 1,387.9 | 122.3 | 13.3 | 8.9 | 48.4 | 4.1 | |
| 281.6 | 10,869.6 | 1,240.1 | 42.2 | 4.1 | 3.6 | 262.3 | 9.0 | |
| 126.2 | 7,107.2 | 645.7 | -25.4 | 6.8 | -1.3 | -- | 3.5 |
Revvity, Inc. provides products, services, and solutions to the diagnostics, life sciences, and applied services markets worldwide. It operates through two segments, Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical... Solutions segment provides instruments, reagents, informatics, software, subscriptions, detection, and imaging technologies that enable scientists to enhance research breakthroughs in the life sciences research market, as well as contract research and laboratory services. It also provides analytical technologies, solutions, and services for its customers to understand the characterize the health of various aspects, including air, water, and soil. In addition, this segment offers solutions to farmers and food producers; and analytical instrumentation for the industrial market, which includes the chemical, semiconductor and electronics, energy, lubricant, petrochemical, and polymer industries. The Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. This segment also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for applications in oncology, immunodiagnostics, and drug discovery. It serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies. The company was formerly known as PerkinElmer, Inc. and changed its name to Revvity, Inc. in April 2023. Revvity, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts. Read more
CEO, Pres & Director
Dr. Prahlad R. Singh Ph.D.
Sr. VP of Global Operations
Mr. Tajinder Vohra
Headquarters
Waltham, MA
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of PerkinElmer Inc (PKI) stood at $ 16,202 Mln as on 31-Mar-23
The share price of PerkinElmer Inc (PKI) is $117.67 (NYSE) as of 15-Jun-2023 09:30 EDT. PerkinElmer Inc (PKI) has given a return of 6.6% in the last 3 years.
PerkinElmer Inc (PKI) has a market capitalisation of $ 14,456 Mln as on 15-Jun-2023. As per Value Research classification, it is a Small Cap company.
The P/B ratio of PerkinElmer Inc (PKI) is 2.57 times as on 15-Jun-2023, a 28% discount to its peers’ median range of 3.56 times.
The P/E ratio of PerkinElmer Inc (PKI) is 41.45 times as on 15-Jun-2023, a 36% discount to its peers’ median range of 64.27 times.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the PerkinElmer Inc (PKI) and enter the required number of quantities and click on buy to purchase the shares of PerkinElmer Inc (PKI).
Revvity, Inc. provides products, services, and solutions to the diagnostics, life sciences, and applied services markets worldwide. It operates through two segments, Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment provides instruments, reagents, informatics, software, subscriptions, detection, and imaging technologies that enable scientists to enhance research breakthroughs in the life sciences research market, as well as contract research and laboratory services. It also provides analytical technologies, solutions, and services for its customers to understand the characterize the health of various aspects, including air, water, and soil. In addition, this segment offers solutions to farmers and food producers; and analytical instrumentation for the industrial market, which includes the chemical, semiconductor and electronics, energy, lubricant, petrochemical, and polymer industries. The Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. This segment also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for applications in oncology, immunodiagnostics, and drug discovery. It serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies. The company was formerly known as PerkinElmer, Inc. and changed its name to Revvity, Inc. in April 2023. Revvity, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.
The CEO & director of Dr. Prahlad R. Singh Ph.D.. is PerkinElmer Inc (PKI), and CFO & Sr. VP is Mr. Tajinder Vohra.
There is no promoter pledging in PerkinElmer Inc (PKI).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,119
|
|
|
876
|
|
|
858
|
|
|
830
|
|
|
787
|
|
|
719
|
|
|
687
|
|
|
687
|
|
|
573
|
| PerkinElmer Inc. (PKI) | Ratios |
|---|---|
|
Return on equity(%)
|
5.44
|
|
Operating margin(%)
|
16.34
|
|
Net Margin(%)
|
11.82
|
|
Dividend yield(%)
|
--
|
Yes, TTM profit after tax of PerkinElmer Inc (PKI) was $972 Mln.
$6.58
(
